Baxter(US:BAX) Businesswire·2025-12-15 14:53Core Viewpoint - Baxter International Inc. is facing a federal securities class action due to allegations of making false and misleading statements regarding the safety and efficacy of its Novum LVP product, which has been linked to serious patient risks [3][4]. Group 1: Allegations Against Baxter - The complaint claims that Baxter and its executives violated federal securities laws by failing to disclose systemic defects in the Novum LVP, which led to malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, posing risks of serious injury or death to patients [3]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures, leading to continued harm to patients [3]. - As a result of these issues, there was an increased risk that customers would be instructed to take existing Novum LVPs out of service, and Baxter would halt all new sales of these pumps [3]. Group 2: Impact on Stock and Legal Proceedings - The extent of the alleged fraud was revealed on July 31, 2025, when Baxter announced a voluntary and temporary pause in shipments and installations of the Novum LVP, causing the stock to drop by 22.4%, closing at $21.76 on the same day [4]. - Investors are reminded of the December 15, 2025 deadline to seek the role of lead plaintiff in the class action lawsuit against Baxter [1].